Raptor Announces Full Enrollment of Phase 2b Trial of RP103 for Non-Alcoholic Fatty Liver Disease in Children
January 13, 2014 07:00 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that its Phase 2b clinical trial, to evaluate the safety and potential efficacy of RP103...
Raptor Submits IND for RP103 for Leigh Syndrome and Other Mitochondrial Disorders
December 10, 2013 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Dec. 10, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has submitted an investigational new drug application (IND) to the U.S. Food and...
Raptor Pharmaceutical Corp. Provides PROCYSBI(R) Launch Update and Third Quarter 2013 Financial Results
November 07, 2013 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today provided financial results for its third quarter and nine months ended September 30, 2013.
PROCYSBI...
Raptor Pharmaceutical to Hold Third Quarter 2013 Financial Results Webcast and Conference Call
October 21, 2013 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release third quarter 2013 financial results after market close on Thursday,...
Raptor Pharmaceutical Announces Presentation at the International Pediatric Nephrology Association Meeting in Shanghai
August 29, 2013 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 29, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that PROCYSBI (cysteamine bitartrate) will be featured in an upcoming presentation at the...
Raptor Pharmaceutical Provides PROCYSBI(TM) Launch Update and Second Quarter 2013 Financial Results
August 08, 2013 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today provided a launch update for PROCYSBI (cysteamine bitartrate) delayed-release capsules and financial...
Raptor Pharmaceutical to Present at Upcoming Investor Conference
July 02, 2013 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., July 2, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Christopher M. Starr, Ph.D., Raptor's CEO, will present an overview of the company at...
Raptor's PROCYSBI(TM) Now Commercially Available in the U.S. for Nephropathic Cystinosis Patients
June 19, 2013 07:00 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., June 19, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that PROCYSBI™ (cysteamine bitartrate) delayed-release capsules are now available in...
Raptor Pharmaceutical to Present at Upcoming Investor Conference
June 12, 2013 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., June 12, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Julie Anne Smith, executive vice president, strategy and chief operating officer of...
Raptor Pharmaceutical Corp. Reports Financial Results for the Transition Period From September 1, 2012 to December 31, 2012
March 14, 2013 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., March 14, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today reported financial results for its four month transition period from...